v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONTINGENTLY REDEEMABLE NONCONTROLLING INTEREST AND EQUITY - USD ($)
$ in Millions
Total
Series C Preferred Stock
Sempra shareholders' equity
Sempra shareholders' equity
Series C Preferred Stock
Preferred stock
Common stock
Retained earnings
Retained earnings
Series C Preferred Stock
AOCI
NCI
Beginning Balance at Dec. 31, 2024 $ 37,788   $ 31,222   $ 889 $ 13,520 $ 16,979   $ (166) $ 6,566
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income 1,438   1,390       1,390     48
Other comprehensive income (loss) (56)   (49)           (49) (7)
Share-based compensation expense 11   11     11        
Dividends declared:                    
Preferred dividends   $ (22)   $ (22)       $ (22)    
Common stock dividends (841)   (841)       (841)      
Preferred dividends of subsidiary (1)   (1)       (1)      
Issuances of common stock 45   45     45        
Repurchases of common stock (58)   (58)     (58)        
CRNCI and NCI activities:                    
Contributions from NCI 83                 83
Distributions to NCI (91)                 (91)
Ending balance at Jun. 30, 2025 38,296   31,697   889 13,518 17,505   (215) 6,599
Beginning Balance at Mar. 31, 2025 38,202   31,643   889 13,484 17,465   (195) 6,559
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income 519   473       473     46
Other comprehensive income (loss) (22)   (20)           (20) (2)
Share-based compensation expense 13   13     13        
Dividends declared:                    
Preferred dividends   $ (11)   $ (11)       $ (11)    
Common stock dividends (421)   (421)       (421)      
Preferred dividends of subsidiary (1)   (1)       (1)      
Issuances of common stock 22   22     22        
Repurchases of common stock (1)   (1)     (1)        
CRNCI and NCI activities:                    
Contributions from NCI 49                 49
Distributions to NCI (53)                 (53)
Ending balance at Jun. 30, 2025 38,296   31,697   889 13,518 17,505   (215) 6,599
Beginning balance at Dec. 31, 2025 [1] 3,206                  
CRNCI                    
Net income 10                  
Allocation of interests 92                  
Ending balance at Jun. 30, 2026 3,308                  
Beginning Balance at Dec. 31, 2025 38,793 [1]   31,594   0 14,699 17,092   (197) 7,199
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income 2,082   1,834       1,834     248
Net income 2,092                  
Other comprehensive income (loss) 58   53           53 5
Share-based compensation expense 44   44     44        
Dividends declared:                    
Common stock dividends (859)   (859)       (859)      
Preferred dividends of subsidiary (1)   (1)       (1)      
Issuances of common stock 55   55     55        
Repurchases of common stock (21)   (21)     (21)        
CRNCI and NCI activities:                    
Allocation of interests (92)   (14)     (14)       (78)
Contributions from NCI 74                 74
Distributions to NCI (135)                 (135)
Ending balance at Jun. 30, 2026 39,998   32,685   0 14,763 18,066   (144) 7,313
Beginning balance at Mar. 31, 2026 3,254                  
CRNCI                    
Net income 4                  
Allocation of interests 50                  
Ending balance at Jun. 30, 2026 3,308                  
Beginning Balance at Mar. 31, 2026 39,474   32,239   0 14,731 17,699   (191) 7,235
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income 938   797       797     141
Net income 942                  
Other comprehensive income (loss) 51   47           47 4
Share-based compensation expense 19   19     19        
Dividends declared:                    
Common stock dividends (429)   (429)       (429)      
Preferred dividends of subsidiary (1)   (1)       (1)      
Issuances of common stock 34   34     34        
Repurchases of common stock (1)   (1)     (1)        
CRNCI and NCI activities:                    
Allocation of interests (50)   (20)     (20)       (30)
Contributions from NCI 33                 33
Distributions to NCI (70)                 (70)
Ending balance at Jun. 30, 2026 $ 39,998   $ 32,685   $ 0 $ 14,763 $ 18,066   $ (144) $ 7,313
[1] Derived from audited financial statements.